Physician profile
Jason B Meier
NPI 1417202326
$500.19
in general payments reported to CMS, 2019-2025
12 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.36 · 2020: $45.65 · 2021: $11.92 · 2022: $61.92 · 2023: $100 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256 · Education: $58.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.81 |
| Education | $58.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galvanize Therapeutics, INC | $214.10 | 2025 | Aliya System |
| Exelixis INC. | $74.97 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.49 | 2019-2023 | Opdivo |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Lilly USA, LLC | $17.93 | 2020 | |
| Agios Pharmaceuticals, INC. | $16.53 | 2023 | Pyrukynd |
| Emd Serono, INC. | $15.28 | 2019 | |
| Glaxosmithkline, LLC. | $14.67 | 2020 | |
| Genentech USA, INC. | $13.41 | 2019 | |
| Pfizer INC. | $12.77 | 2019 | |
| Janssen Biotech, INC. | $12.12 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.